SITC Publishes First Kidney Cancer Treatment Guideline to Focus on Immunotherapy

The first evidence-based consensus statement on cancer immunotherapy for the treatment of patients with the most common type of kidney cancer, renal cell carcinoma, has been published by the Society for Immunotherapy of Cancer (SITC) in the Journal for ImmunoTherapy of Cancer by Rini et al. The guideline provides expert recommendations and consensus opinion surrounding the use of interferon-α (IFN-α) and interleukin-2 (IL-2) in renal cell carcinoma. In addition, it … (leggi tutto)